Henrik Lundvall

Modern weight loss medicines are a treatment option for overweight and obesity that work by affecting the body’s biological signals related to appetite and fullness.

Overweight and obesity are influenced by complex biological, hormonal, and metabolic factors. With the right treatment, it may become easier to achieve sustainable weight loss while also reducing the risk of weight-related health conditions.

Obesity and overweight are not simply about willpower. They are influenced by the body’s biological systems that regulate hunger and fullness. GLP-1-based medicines are a modern treatment for medical weight management that can help regulate appetite, increase feelings of fullness, and support more sustainable weight loss and long-term lifestyle changes.

Mounjaro is a prescription medicine used to treat obesity and overweight. The active ingredient, tirzepatide, works by affecting the body’s biological systems involved in hunger, fullness, and blood sugar regulation, which may help reduce appetite and increase feelings of fullness.

The treatment is given as an injection once a week and is combined with lifestyle changes. In clinical studies, tirzepatide has shown good results for weight loss in people living with overweight and obesity.

Food noise involves persistent, unwanted, and tiring thoughts about food that can negatively affect quality of life. Unlike regular thoughts about food, food noise is often stressful and intrusive, revolving around hunger and cravings as well as rules, timing, and control. Food noise is a relatively new concept in research and puts into words something that many have recognized for a long time.

Semaglutide is an active pharmaceutical substance used for obesity and type 2 diabetes. Clinical studies have shown significant effects on both weight and metabolic risk factors. Interest in treatment with semaglutide has increased in line with documented results and a growing role in modern obesity care.

Weight gain after stopping GLP-1 medication is common and is partly due to appetite regulation, hunger, and energy balance gradually returning to previous levels when treatment ends. Obesity is a chronic and complex disease where biological mechanisms affect hunger, satiety, and body weight over time.

When treating with weight loss medications like Wegovy (semaglutide) and Mounjaro (tirzepatide), it is important to consider how the medications can affect fertility and the efficacy of contraceptives. Medications such as semaglutide (Ozempic, Wegovy, Rybelsus) and tirzepatide (Mounjaro) can contribute to improved fertility in women with obesity, partly as a result of weight loss and improved hormonal and metabolic function. At the same time, they can affect the absorption and efficacy of oral contraceptives.

Rybelsus is an oral treatment option used for type 2 diabetes and which in some cases may be relevant within obesity treatment. The medication contains the active substance semaglutide – the same substance as in Ozempic and Wegovy – and works by mimicking the body's own satiety hormone GLP-1. This contributes to reduced appetite, increased feeling of fullness, and delayed gastric emptying.

‍

Mounjaro contains the active substance tirzepatide and is used for the treatment of adults with type 2 diabetes as a supplement to diet and exercise. The medication contributes to lowering blood sugar levels in a glucose-dependent manner.

Mounjaro is also used for the treatment of adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27 kg/m² with at least one weight-related complication). By affecting the body's appetite regulation, the treatment can contribute to weight loss through reduced energy intake.